AR122023A1 - Péptidos y métodos para el tratamiento de esclerosis múltiple - Google Patents

Péptidos y métodos para el tratamiento de esclerosis múltiple

Info

Publication number
AR122023A1
AR122023A1 ARP210101235A ARP210101235A AR122023A1 AR 122023 A1 AR122023 A1 AR 122023A1 AR P210101235 A ARP210101235 A AR P210101235A AR P210101235 A ARP210101235 A AR P210101235A AR 122023 A1 AR122023 A1 AR 122023A1
Authority
AR
Argentina
Prior art keywords
treatment
peptides
methods
multiple sclerosis
cells
Prior art date
Application number
ARP210101235A
Other languages
English (en)
Inventor
Jean Saint-Remy
- Vander Elst Luc Marie
Milos Erak
Vincent Carlier
Rampelbergh Jean Van
Mechelen Marcelle Van
David Walgraffe
Geoffrey Gloire
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of AR122023A1 publication Critical patent/AR122023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

La invención se relaciona con péptidos inmunogénicos derivados de la Glicoproteína de Oligodendrocito de Mielina (MOG) para uso en el tratamiento de trastornos desmielinizantes y la generación de células T CD4+ citolíticas o células NKT contra células que presentan antígenos que presentan la secuencia del epítopo MOG salvaje.
ARP210101235A 2020-05-06 2021-05-06 Péptidos y métodos para el tratamiento de esclerosis múltiple AR122023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20173201 2020-05-06

Publications (1)

Publication Number Publication Date
AR122023A1 true AR122023A1 (es) 2022-08-03

Family

ID=70613608

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101235A AR122023A1 (es) 2020-05-06 2021-05-06 Péptidos y métodos para el tratamiento de esclerosis múltiple

Country Status (16)

Country Link
US (1) US20230340061A1 (es)
EP (1) EP4146676A2 (es)
JP (1) JP2023525084A (es)
KR (1) KR20230006905A (es)
CN (1) CN115702162A (es)
AR (1) AR122023A1 (es)
AU (1) AU2021210629A1 (es)
CA (1) CA3181368A1 (es)
CO (1) CO2022017087A2 (es)
CU (1) CU20220066A7 (es)
IL (1) IL297945A (es)
MX (1) MX2022013911A (es)
PE (1) PE20240491A1 (es)
TW (1) TW202208413A (es)
WO (1) WO2021148683A2 (es)
ZA (1) ZA202212773B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
ES2650236T3 (es) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
HUE055070T2 (hu) * 2010-11-25 2021-10-28 Imnate Sarl Immunogén peptidek fertõzõ betegségek, autoimmun betegségek, allofaktorokra adott immunválaszok, allergiás betegségek, tumorok, graftkilökõdés, és génterápiához vagy génvakcinációhoz alkalmazott vírusvektorokkal szembeni immunválaszok megelõzésében és/vagy kezelésében történõ alkalmazásra
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
KR20240015731A (ko) * 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드

Also Published As

Publication number Publication date
KR20230006905A (ko) 2023-01-11
CA3181368A1 (en) 2021-07-29
TW202208413A (zh) 2022-03-01
WO2021148683A3 (en) 2021-09-23
WO2021148683A2 (en) 2021-07-29
CO2022017087A2 (es) 2023-02-16
PE20240491A1 (es) 2024-03-15
ZA202212773B (en) 2024-04-24
CU20220066A7 (es) 2023-06-13
MX2022013911A (es) 2022-11-30
AU2021210629A1 (en) 2022-12-08
IL297945A (en) 2023-01-01
CN115702162A (zh) 2023-02-14
JP2023525084A (ja) 2023-06-14
EP4146676A2 (en) 2023-03-15
US20230340061A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
CO2022017087A2 (es) Péptidos y métodos para el tratamiento de esclerosis múltiple
BR112021025035A2 (pt) Composições e métodos para imunoterapia contra câncer
Carreño et al. Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112016000810A2 (pt) imunoterapia contra vários tumores tais como câncer de pulmão, incluindo cpcnp
MX363182B (es) Composiciones que comprenden mezclas de alcanos semifluorados.
BR112018071466A2 (pt) novos peptídeos de ligação a cd1d imunogênicos
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
PE20211494A1 (es) Peptidos inmunogenicos con motivos de oxidorreductasa mejorados
DOP2020000082A (es) Administración oral de análogos del péptido glp-1
CL2019003423A1 (es) Nuevos péptidos (seq id n°378), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
BR112021025477A2 (pt) Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
Beijnen et al. Vaccine-induced CD8+ T cell responses in children: A review of age-specific molecular determinants contributing to antigen cross-presentation
Kogo et al. Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo
MX2022006022A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
CO2024000603A2 (es) Péptidos y métodos para el tratamiento de neuromielitis óptica
BR112021018684A2 (pt) Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+
MX2021015643A (es) Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
BR112021017691A2 (pt) Formulações imunogênicas para o tratamento do câncer
MX2021001357A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
SG10201900879PA (en) Cdca1-derived peptide and vaccine containing same
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos